Lundbeck beats 1st-qtr sales expectation

12 May 2020
lundbeck_headquarters_3_large

Danish CNS specialist Lundbeck (LUND: CO) today posted first-quarter 2020 financials, noting that revenues reached 4,564 million Danish kroner ($661.3 million), a rise of 8% (+7% in local currencies), above an average of 4.34 billion kroner forecast by analysts in a Refinitiv Eikon poll. Key brands registered cumulative growth of 35%.

Core earnings before interest and taxes (EBIT) came in at 1,357 million kroner, down 4%. On a reported basis, EBIT was 338 million kroner, down 72%. Core earnings per share were 4.89 kroner, down 11%.

Lundbeck shares rose 2.75% to 253.80 kroner in early trading, but drifted back to 245.50 kroner by late morning

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical